Susan Drapeau
Senior Principal, Regenerative Medicine Dark Horse Consulting Group
Dr. Drapeau has over 25 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Currently with Dark Horse Regenerative Medicine, Susan leads projects with numerous client partners across development, landscape assessment, regulatory strategy, manufacturing tech transfer, and business evaluation to accelerate their portfolio. Prior to Dark Horse Consulting, Dr. Drapeau was a key contributor at Sigilon Therapeutics, Vericel Corporation, Medtronic and Osiris Therapeutics. Dr. Drapeau holds a PhD in chemical engineering from Rice University.
Seminars
Wednesday 23rd September 2026
When Will Big Pharma Join the EV Party?
2:00 pm
- Examining the key barriers limiting Big Pharma investment and participation in the exosome therapeutics landscape
- Evaluating the impact of regulatory uncertainty, manufacturing challenges, clinical validation requirements, and commercial considerations on adoption decisions
- Identifying the scientific, clinical, and business milestones needed to transition exosome therapeutics into a mainstream pharmaceutical modality
